Liraglutide mainly inhibited osteoclast differentiation and alleviated bone deterioration and bone loss caused by STZ + OVX-induced rat models (Wen et al., 2018)
Thats why the medication forms are receptor agonists
J.GaoF.ZengY
Four or five years ago I was saying, What are we doing? he notes
The ongoing FLOW trial (NCT03819153) will be the first large multinational randomised placebo-controlled trial to primarily investigate the effects of a GLP1-RA, once-weekly subcutaneous semaglutide, on major kidney outcomes in adults with type 2 diabetes and CKD [50]
Although, no molecular mechanism was provided, their results are consistent with the notion that some, if not all, of the metabolic effects of the parent peptide may be mediated by our discovery that the metabolite GLP-1(2836) inhibits MTP and shifts energy substrate utilization from fatty acids to glucose